Inflammation and Depression in People With HIV

Launched by EMORY UNIVERSITY · Apr 27, 2023

Keywords

ClinConnect Summary

This clinical trial is investigating how inflammation may affect symptoms of depression, such as a lack of enjoyment in daily activities (called anhedonia) and slowed physical movements in people living with HIV. Over 10 weeks, 60 participants—both men and women—who have HIV and are experiencing depression with high levels of inflammation will receive either an anti-inflammatory medication called baricitinib or a placebo (a look-alike pill with no active drug). To be eligible, participants need to be stable on their HIV treatment, have a certain level of inflammation, and show signs of depression.

Participants in the study can expect to undergo various assessments, including lab tests, mental health evaluations, brain scans (using a technique called fMRI), and possibly spinal taps. The entire study will take about five months, and individuals must meet certain criteria to join, such as being between 18 and 65 years old and currently not taking antidepressants. This research aims to better understand the connection between inflammation and depression in individuals with HIV, potentially leading to new treatment options in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • HIV infected on continuous antiretroviral therapy (ART) with plasma HIV RNA \<200 copies/ml for at least 12 months (on at least two previous clinic visits and confirmed at screening)
• • Current cluster of differentiation 4 (CD4+) \> 350 cells/microliter for at least twelve months (on at least two previous clinic visits and confirmed at screening)
• • A primary diagnosis of Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V) major depression, current, or Bipolar, depressed type as diagnosed by the SCID-V
• • Score of ≥10 on the 9-item Patient Health Questionnaire (PHQ-9)
• • Off all antidepressant or other psychotropic therapy (e.g. mood stabilizers, antipsychotics, and sedative hypnotics) for at least 4 weeks (8 weeks for fluoxetine) or on a stable psychotropic regimen for at least 4 weeks prior to baseline visit
• • Significant anhedonia as reflected by a score ≥ 2 on item #1 of the PHQ-9
• • CRP≥2mg/L
• • Women of reproductive age will have a negative serum pregnancy test at study entry and both mend and women must agree to adequate contraception while
• Exclusion Criteria:
• • \< 18 years of age or \> 65 years of age
• • Pregnancy or breastfeeding
• • Significant hematological abnormalities at screening (ANC \< 1500, Hgb\<10, platelet\< 100,000)
• • History of progressive multifocal leukoencephalopathy
• • Untreated latent tuberculosis infection (which will be screened for prior to entry)
• * Having taken the following immunosuppressive medications within the past 6 months:
• • 1. Oral corticosteroids
• • 2. Biologic treatments such as etanercept, infliximab, certolizumab, adalimumab, golimumab, tocilizumab, abatacept, Ustekinumab, ixekizumab, secukinumab, or anakinra
• • 3. Cyclophosphamide (or any other cytotoxic agent), belimumab, or anifrolumab (or another anti-interferon (IFN) therapy)
• • 4. Rituximab, any other B cell depleting therapies, or intravenous immunoglobulin (IVIg)
• • 5. any Janus kinase (JAK) inhibitor
• • History of deep venous thrombosis
• * Cardiovascular disease:
• • 1. Coronary artery disease or history of myocardial infarction
• • 2. Congestive heart failure with left ventricular ejection fraction ≤40% per American Heart Association guidelines
• • 3. Stroke history
• • Hematologic malignancies including lymphoma and leukemia
• • Major surgery within 8 weeks prior to screening or will require major surgery during the study
• • Current or recent (\<4 weeks prior to randomization) clinically serious viral (including coronavirus disease 2019 (COVID-19)), bacterial, fungal, or parasitic infection or any other active or recent infection
• • Symptomatic herpes simplex at the time of randomization
• • Symptomatic herpes zoster infection within 12 weeks prior to randomization
• • History of disseminated/complicated herpes zoster (for example, ophthalmic zoster or CNS involvement)
• * Positive test for hepatitis B virus (HBV) defined as:
• • 1. positive for hepatitis B surface antigen (HBsAg), or
• • 2. positive for hepatitis B core antibody (HBcAb) and positive for hepatitis B virus deoxyribonucleic acid (HBV DNA)
• • Hepatitis C virus (HCV) infection (hepatitis C antibody-positive and HCV ribonucleic acid \[RNA\]-positive)
• • Cirrhosis of the liver from any cause
• * Any of the following specific abnormalities on screening laboratory tests:
• • 1. alanine transaminase (ALT) or aspartate aminotransferase (AST) \>2 x upper limits of normal (ULN)
• • 2. alkaline phosphatase (ALP) ≥2 x ULN
• • 3. total bilirubin ≥1.5 x ULN (with the exception of patients on atazanavir, who must have total bilirubin \<2 x ULN)
• • Chronic kidney disease with estimated glomerular filtration rate (eGFR) \<40 mL/min/1.73 m\^2
• • History of any (non-mood-related) psychotic disorder; active psychotic symptoms of any type; substance abuse/dependence within 6 months of study entry, as determined by severe combined immunodeficiency (SCID)
• • A positive urine drug screen for illicit drugs at any time during the study excluding marijuana
• • An active suicidal plan as determined by a score \>3 on item #3 on the Hamilton Rating Scale for Depression (HAM-D)
• • An active eating disorder or antisocial personality disorder
• • History of dementia
• • Chronic use of non-steroidal anti-inflammatory agents (NSAIDS) (excluding 81mg of aspirin), glucocorticoid containing medications or minocycline within 2 weeks of baseline or at any time during the study
• • Any contraindication for MRI scanning
• • Failure of more than 2 antidepressant trials (at least 6 weeks at recommended dose) in the current episode or 5 antidepressant trials lifetime
• • BMI \>42 (to exclude severe obesity) or at the investigator's discretion based on the patient's ability to fit in the MRI scanner